Grace Therapeutics annual free cash flow
2023
2024
2025
Grace Therapeutics Free Cash Flow (FCF) History (GRCE)
Grace Therapeutics reported −$14.9M in free cash flow for fiscal 2025, a decrease of $2.5M from the previous fiscal year.
View full Grace Therapeutics company overviewGrace Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-03-31 | −$14.9M | −$2.5M | — | — |
| 2024 | 2024-03-31 | −$12.4M | $3.6M | — | — |
| 2023 | 2023-03-31 | −$15.9M | — | — | — |
Grace Therapeutics quarterly free cash flow
Q1.20
Q1.21
Q3.23
Q3.24
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q3 2024 | 2023-12-31 | −$1.9M | — | — | — |
| Q3 2023 | 2022-12-31 | −$3.7M | — | — | — |
| Q1 2021 | 2020-06-30 | −$4.2M | — | — | — |
| Q1 2020 | 2019-06-30 | −$6.8M | — | — | — |
Grace Therapeutics free cash flow growth trends
Grace Therapeutics's latest reported quarter, Q3 2024, generated −$1.9M in free cash flow.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Grace Therapeutics filings at SEC.gov ↗